Runs clinical trials for gedatolisib, a cancer drug designed to block a tumor signaling pathway at two points instead of one.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleRevenue is in the bottom 5% globally
Runs clinical trials for gedatolisib, a cancer drug designed to block a tumor signaling pathway at two points instead of one.
What this company is and how it runs — written from structure, not news.
Celcuity is developing a single drug, gedatolisib, that blocks two connected points in a cell-signaling pathway that drives certain breast cancers — the entry point, PI3K, and a downstream node, mTORC1/2 — because blocking only the entry point allows tumors to stay alive through the downstream route, which is how patients on existing PI3K inhibitors eventually stop responding. Closing both nodes at once is the scientific reason Celcuity is running a Phase 3 trial in hormone receptor-positive HER2-negative breast cancer rather than simply using a drug already approved, but that same completeness of blockade suppresses the pathway more aggressively than selective inhibitors do, which is what produces the elevated side-effect signal that has to be managed at every dose. The trial's outcome depends on whether gedatolisib can hit FDA's progression-free survival threshold at a dose patients can tolerate — if the gap between a tumor-suppressing dose and a harmful dose turns out to be too small, the dual-blocking mechanism that separates gedatolisib from approved drugs is simultaneously the reason it cannot pass FDA review. Enrollment itself is an additional bottleneck, because only patients whose tumors carry confirmed PI3K pathway mutations qualify, so the speed at which oncology centers can identify and screen those specific patients sets the clock on when the company can accumulate enough data to file.
How does this company make money?
The company has no revenue right now. It is still in clinical trials and has not sold a single dose commercially. If gedatolisib receives FDA approval, the plan is to sell it through specialty oncology distributors and hospital pharmacy procurement systems, charging per unit sold.
What makes this company hard to replace?
Oncology investigators running the Phase 3 trial cannot switch to a different PI3K or mTOR drug without shutting down the current trial, filing a new Investigational New Drug application with FDA, rewriting the protocol, and restarting enrollment — a process that takes multiple years. Patients already enrolled cannot move to a competing drug without losing their place in the study and losing access to gedatolisib's specific dual mechanism, which no currently approved drug replicates.
What limits this company?
Not every breast cancer patient qualifies. Only patients whose tumors show confirmed activation of the PI3K/AKT/mTOR pathway can enroll, and finding those patients requires a companion diagnostic test that must be run at each trial site. The more slowly those tests identify eligible patients, the longer it takes to collect enough data to submit to FDA.
What does this company depend on?
The company cannot operate without five things: the FDA Investigational New Drug application that permits human testing of gedatolisib; contract research organizations that run the day-to-day operations of the Phase 3 trial; specialized oncology centers with Good Clinical Practice certification that enroll and treat patients; companion diagnostic assays that detect the PI3K/mTOR pathway biomarkers required for patient eligibility; and facilities manufacturing clinical-grade gedatolisib under current Good Manufacturing Practices.
Who depends on this company?
Hormone receptor-positive breast cancer patients enrolled at participating clinical sites would lose access to gedatolisib's dual-node inhibition if the program stopped. Oncology centers running the trial would lose both the study protocol and the research funding tied to it. Contract research organizations managing the Phase 3 programs would lose that trial revenue.
How does this company scale?
Enrolling more patients across existing trial sites and collecting their data adds relatively little cost — the process replicates efficiently once a site is up and running. What does not scale easily is making the drug itself. Manufacturing clinical-grade gedatolisib requires specialized facilities built to handle dual pathway inhibitor chemistry, and expanding that production means building new Good Manufacturing Practice capacity, which is slow and expensive.
What external forces can significantly affect this company?
If Medicare or private insurers decide they will not cover PI3K inhibitors at the prices a specialty drug commands, the commercial case for gedatolisib weakens even if it gets approved. FDA is also raising the bar on what counts as a sufficient progression-free survival result in breast cancer trials, which could make the endpoints harder to hit. And as existing PI3K inhibitors lose their patents and face generic competition, the market gedatolisib would enter becomes more crowded and price-pressured.
Where is this company structurally vulnerable?
If FDA concludes, either at a pre-approval meeting or in a formal rejection letter, that gedatolisib's side effects at the dose required to suppress tumors are too severe for the breast cancer patients it would treat, the drug has no path to approval. The problem is structural: the same feature that makes gedatolisib more effective than single-node drugs — blocking both steps of the pathway — is also what makes it harder on patients. No adjustment to the trial design can fix that, because the efficacy and the toxicity come from the same mechanism.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Three price-behavior observations have aligned: the ulcer index (drawdown depth and duration composite) is elevated, current drawdown from peak is significant, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph